Logo

    lifesciences

    Explore " lifesciences" with insightful episodes like "Trends Talk by Kanaal Z met Hans Casier, voorzitter essenscia", "Trends Talk by Kanaal Z met Hans Casier, voorzitter van essenscia", "Why Private Equity firms are betting big on clinical research sites", "Kanazawa University NanoLSI Podcast: Genetic switches in tumor development" and "EP101: Catalyze Success in Business and Scientific Frontiers with Urban A. Kiernan, Ph.D" from podcasts like ""Trends Podcast", "Trends Talk", "DarshanTalks Podcast", "Kanazawa University NanoLSI Podcast" and "The Millionaire Mind"" and more!

    Episodes (11)

    Trends Talk by Kanaal Z met Hans Casier, voorzitter essenscia

    Trends Talk by Kanaal Z met Hans Casier, voorzitter essenscia
    Duurzame industrie mag en moet in Europa, maar dan liefst een industrie die kan optornen tegen de concurrentie in de VS of Azië. Zoniet hebben we op termijn helemaal geen industrie meer in Europa. Samengevat is dat zowat het punt van de meer dan 70 grote industriëlen die afgelopen week in Antwerpen zijn samengekomen voor een conferentie. Vooral onze energie-intensieve industrie staat onder druk, en een voorbeeld daarvan zijn de chemische bedrijven. Onze studiogast is dan ook Hans Casier. Hij is zelf een chemie-industrieel, en voorzitter van de Belgische chemiefederatie essenscia.

    Trends Talk by Kanaal Z met Hans Casier, voorzitter van essenscia

    Trends Talk by Kanaal Z met Hans Casier, voorzitter van essenscia
    Duurzame industrie mag en moet in Europa, maar dan liefst een industrie die kan optornen tegen de concurrentie in de VS of Azië. Zoniet hebben we op termijn helemaal geen industrie meer in Europa. Samengevat is dat zowat het punt van de meer dan 70 grote industriëlen die afgelopen week in Antwerpen zijn samengekomen voor een conferentie. Vooral onze energie-intensieve industrie staat onder druk, en een voorbeeld daarvan zijn de chemische bedrijven. Onze studiogast is dan ook Hans Casier. Hij is zelf een chemie-industrieel, en voorzitter van de Belgische chemiefederatie essenscia.

    Why Private Equity firms are betting big on clinical research sites

    Why Private Equity firms are betting big on clinical research sites

    We delve into the growing allure of clinical research sites and organizations for private equity firms. Backed by BPOC, these investments signify more than just single business deals; they are a testament to the increasing interest in fueling healthcare innovation and services.

    As this trend gains momentum, thorough due diligence becomes crucial in navigating the complexities of these acquisitions. The Kulkarni Law Firm, specializing in Life Sciences law, plays a pivotal role in providing comprehensive support for regulatory compliance, contract reviews, and risk assessments. Daron emphasizes that these investments go beyond financial gains, contributing to the redefinition of the healthcare investment landscape.

    The Kulkarni Law Firm keeps a watchful eye on the latest updates from the Department of Justice (DOJ), Office of Inspector General (OIG), and the Food and Drug Administration (FDA), ensuring that clients are well-informed and compliant. 


    Kanazawa University NanoLSI Podcast: Genetic switches in tumor development

    Kanazawa University NanoLSI Podcast: Genetic switches in tumor development

    Genetic switches in tumor development

    Hello and welcome to the NanoLSI podcast. Thank you for joining us today. In this episode we feature the latest research by Masanobu Oshima at the Kanazawa University NanoLSI.

    The research described in this podcast was published in Cancer Research in November 2023

    Kanazawa University NanoLSI website

    https://nanolsi.kanazawa-u.ac.jp/en/

    Genetic switches in tumor development

    Researchers at Kanazawa University report in Cancer Research how Kras and p53 mutations influence the tumor suppressor and promoter functions of a TGF- ß pathway. The findings may lead to a new approach for colorectal cancer therapy.

    Both the progression and the suppression of tumors are governed by biomolecular processes. Often, a particular process is involved in either cancer progression or suppression. Cancer treatment in the form of drugs then typically focuses on the respective deactivation or activation of the relevant biomolecular process. However, it has been established that a process known as transforming growth factor ß (TGF-ß) signaling*1 plays a role in both tumor suppression and progression. Now, Masanobu Oshima from Kanazawa University and colleagues have studied the precise genetic conditions underlying the outcome of TGF-ß signaling. Their findings may help the development of new therapeutic strategies for particular cancers.

    The suppressive effect of TGF-ß signaling happens through the stimulation of cell differentiation — the process through which dividing cells acquire their type or function. The malignant progression of cancers, on the other hand, comes from a process called epithelial-mesenchymal transition (EMT), in which an epithelial cell transforms into a mesenchymal cell type. The former is a ‘stationary’ type of cell, found in epithelial tissue, whereas the latter is a more ‘migratory’ type of cell found in development and cancer.

    So how did they investigate these processes and what did they found out?

    Oshima and colleagues performed experiments with tumor-derived organoids. They confirmed that TGF-ß family cytokine, activin plays a role in tumor suppression and progression dependent on the mutation types of driver genes. In certain cancer cells treated with activin, the researchers noted that the partial EMT is induced with tumor aggressiveness and development. On the other hand, certain mutated activin receptors were found to have cancer suppressor capabilities, which made the scientists conclude that genetic alterations underlie the dual function of activins.

    One of the two relevant genes is Kras which relays signals that regulate cell growth, division and differentiation. Oshima and colleagues found that a mutation of Kras blocks TGF-ß/activin-induced growth suppression. The other gene is known as Trp53, which encodes tumor protein 53, playing an important role in cancer regulation. A combination of Kras and Trp53 mutations at hot spots, known as gain-of-function mutation, was found to not just block tumor suppression but promote partial EMT and tumor proliferation.

    The experiments were done with mouse intestinal tumor-derived organoids with defined genetic backgrounds, which makes the results relevant for therapeutic strategies for human colorectal cancer. Quoting the scientists: “Based on these results, the control of TGF- ß/activin signaling appears to be an important preventive and therapeutic strategy against the malignant progression of colorectal cancer carrying […] mutations”.

    Reference

    Dong Wang, Mizuho Nakayama, Chang Pyo Hong, Hiroko Oshima, and Masanobu Oshima. Gain-of-function p53 mutation acts as a genetic switch for T

    NanoLSI Podcast website

    EP101: Catalyze Success in Business and Scientific Frontiers with Urban A. Kiernan, Ph.D

    EP101: Catalyze Success in Business and Scientific Frontiers with Urban A. Kiernan, Ph.D

    In today's episode, we sit down with Urban A. Kiernan, Ph.D., who walks us through the systematic approach to research and business that defines his success. Get ready for an exploration into the principles fueling his achievements and learn from an expert at the forefront of entrepreneurship and scientific innovation. Hit that play button now!


    Key takeaways to listen for


    Advantages of understanding the science of business and starting a career from it 
    Biopharma: What it is, its objectives, and how it differs from pharma  
    What happens if you focus more on what you’re good at 
    The power of leading with passion in your company 
    Key lessons jiu-jitsu can teach entrepreneurs 


    Resources mentioned in this episode


    Top Doctor Magazine: https://topdoctormagazine.com/
    Intrinsic Bioprobes, Inc.: https://intrinsicbio.com/
    National Institutes of Health (NIH): https://www.nih.gov/
    Johnson & Johnson: https://www.jnj.com/
    Cartoon Network: https://www.cartoonnetworkasia.com/
    How to Lie with Statistics by Darrell Huff: https://amzn.to/3QQhkag 


    About Urban A. Kiernan, Ph.D


    Urban is the founder, chairman, and CEO of iMetabolic Biopharma Corporation (iMBP). Urban has over 22 years of industry business and research experience. He is a seasoned BioTech leader with decades of industry business and scientific research experience. He received his M.Sc. and Ph.D. from Arizona State University and is a devoted husband, father, and Jiu Jitsuka. He has authored more than 45 peer-reviewed publications, 4 book chapters, and received 11 patent awards. Urban and a fantastic team of experts are continuously working on the innovative iPlatform™ biotechnology.


    Connect with Dr. Kiernan


    Website: iMetabolic Biopharma Corporation: https://imbiopharma.com/ | Thermo Fisher Scientific: https://www.thermofisher.com/
    LinkedIn: Urban A. Kiernan, Ph.D.: https://bitly.ws/32QA6
    Instagram: @light_bearer: https://bitly.ws/32QAh 


    CONNECT WITH US


    Want to learn more about passive investing in multifamily? Whether you’re looking for investment or coaching opportunities, visit our website at https://investwithrev.com/ to schedule a call, and don’t forget to sign up for our newsletter.


    Go to https://www.themillionairemind.us/ and ask Dallon all your burning questions about how you can start owning apartments today!

    Insights on Careers in Life Sciences with Laura Randa

    Insights on Careers in Life Sciences with Laura Randa

    In this episode of the Hello Career Guru Salon, Suzanna meets with Laura Randa, Present Global Vice President, to discuss ways that women can become successful in a career in life sciences. Previously featured on our Reimagining Your Future - Exploring Career Paths in the Life Sciences Panel, Laura gives you the guidance and expertise you need to build your dream career in the world of Life Science.

    Coffee Pod #80 Micro biologies to macro environmental trends with Professors Jill Banfield and Karen Day

    Coffee Pod #80 Micro biologies to macro environmental trends with Professors Jill Banfield and Karen Day

    Two preeminent female professors discuss careers in science and leadership in #STEMM reflecting on what the world needs today. Thanks to #COVID there has never been a better time to be talking about the relevance of research, diversity in science, and the interconnectedness of public health microbial health and climate science. The qualities of resilience and integrity come through strongly and both Professors advocate passionately for ways to see more women leading organisations in #STEMM. 

    Meet Professor Karen Day – the Advanced Life Sciences Award winner in 2015.

    Professor Karen Day is an infectious disease epidemiologist dedicated to improving global public health.  She is a microbe hunter describing the diversity of malaria parasites globally to improve disease surveillance and control. She has extensive international experience leading field programmes in malaria endemic areas of East, West and Southern Africa, India, Southeast Asia, Papua New Guinea and South America. She is a founder of the scientific discipline of malaria genomic epidemiology.  She has a strong track record of mentoring junior scientists.  

    Professor Day is also an experienced educator and academic administrator in medicine and science having held senior leadership posts in universities in the UK, US and Australia. Highlights include being recruited to University of Oxford in 1993 where she was soon promoted to Professor for her scholarship and leadership. She is an Emeritus Fellow of Hertford College, having been one of the first women science “dons” at that College.  

    From 2004-13, Professor Day led the development of interdisciplinary global public health programs as Director of the Institute of Urban and Global Health at New York University. Most recently she has been the Dean of Science at University of Melbourne. Her profile as a manager is a change agent, building new enterprises and restructuring to improve organizational achievement. She now continues her malaria epidemiology research at the University of Melbourne.

    Meet Professor Jill Banfield, the Advance Life Sciences 2020 Award Winner.

    A mineralogist-turned-microbiologist, Professor Jill Banfield has made outstanding contributions to our knowledge of the structure of microbial communities in natural environments and the human body. 

    Her pioneering work created the platform to explore the role of gut bacteria in health and disease in humans. 

    Her contributions to geosciences are also significant, culminating with her recognition by the American Academy of Sciences, the Royal Society and Australian Academy of Science. 

    In addition to being a brilliant and distinguished scientist, Jill is a wise and generous mentor. 

    She has trained many of the up-and-coming stars of her field and has strongly supported their career advancement.

    Born in Armidale, Jill Banfield was educated at the Australian National University where she completed her bachelor's and master's degree, before gaining a PhD in Earth and Planetary Sciences from Johns Hopkins University. 

    Jill was a faculty member between 1990 – 2001 at University of Wisconsin - Madison and University of Tokyo.

    Since 2001, she has been a researcher and professor at the University of California Berkeley with an appointment in the earth and environmental sciences at Lawrence Berkeley National Laboratory. 

    Jill leads the Microbial Research initiative within the Innovative Genomics Institute, is affiliated with Lawrence Berkeley National Laboratory and has a position at the University of Melbourne, Australia.

    See omnystudio.com/listener for privacy information.

    Reimagining Your Future - Exploring Career Paths in the Life Sciences Panel

    Reimagining Your Future - Exploring Career Paths in the Life Sciences Panel

    In this episode of the Guru Salon, Suzanna hosts a panel of top healthcare executives including Denise D’ Agostino, Laura Randa, Lisa Miller and Nerissa Kreher to help you learn more about a career in the Life Sciences. Giving advice from breaking into the industry to dealing with traditionally hands-on work in the remote age, these panelists give you the advice needed to kickstart your journey and build the life science career of your dreams. Even if you are not looking to start a career in life sciences or change industries, these high-achieving women's insights and stories can be universally applied.